Arix Bioscience Plc - Company Profile
Powered by 
All the data and insights you need on Arix Bioscience Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Arix Bioscience Plc Strategy Report
- Understand Arix Bioscience Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Arix Bioscience Plc (Arix Bioscience) is a global venture capital company, which invests exclusively in diverse healthcare and life science companies. It sources and finances the companies for accelerating the commercialization of their novel medical innovations. Its investment portfolio encompasses companies that develop therapies to address the unmet medical need of oncology, orphan diseases, infectious diseases, and gene therapies. It works in collaboration with universities, research institutions, and biopharmaceutical companies for advancing new technologies. The company serves both public and private sector companies. It has subsidiaries in Scotland, Australia, the US, and the UK. Arix Bioscience is headquartered in London, the UK.
Headquarters
United Kingdom
Address
Duke Street House, 50 Duke Street, London, England, W1K6JL
Website
arixbioscience.com
Telephone
44 20 72901050
No of Employees
7
Industry
Financial Services
Ticker Symbol & Exchange
ARIX (LON)
Revenue (2022)
$138,100
-67.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
54.9%
(2022 vs 2021)
Market Cap*
$182.8M
Net Profit Margin (2022)
XYZ
-37.0%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Services |
|---|
| Funding |
| Venture Capital |
| Operational Support |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In October, the company's Imara Inc entered into an agreement to merge with Enliven Therapeutics. |
| 2020 | Divestiture | In December, the company sold its stake in VelosBio. |
| 2020 | Acquisitions/Mergers/Takeovers | In September, the company completed a seed investment in a new portfolio company, Twelve Bio. |
Competitor Comparison
| Key Parameters | Arix Bioscience Plc | Kings Arms Yard VCT PLC | Northern 3 VCT PLC |
|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom |
| City | London | London | Newcastle Upon Tyne |
| State/Province | England | England | England |
| No. of Employees | 7 | - | - |
| Entity Type | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert Lyne | Chief Executive Officer; Director; General Counsel | Executive Board | 2021 | - |
| Peregrine Moncreiffe | Chairman | Non Executive Board | 2021 | - |
| Isaac Kohlberg? | Director | Non Executive Board | 2021 | - |
| Laura Craig | Investor Relations Officer | Senior Management | - | - |
| Felix Breyer, PhD | Associate | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward